Aegle Therapeutics Corp. Announces the Election of Matthew Vogelhuber to its Board of Directors

Share Article

Matt Vogelhuber Elected to Aegle's Board of Directors

Aegle Therapeutics Corp. announces the election of Matthew Vogelhuber to its Board of Directors, effective immediately.

"We are pleased to welcome Matt to Aegle’s Board," said Shelley A. Hartman, Chief Executive Officer of Aegle Therapeutics. "Matt’s extensive experience in the pharmaceutical industry in addition to his established pharmaceutical relationships will bring significant value to Aegle.”

Matt brings to Aegle over 35 years of pharmaceutical/biotech experience in sales, marketing, strategy, business development and general management, within both the U.S. and international markets. He is currently the Principal and Managing Partner at PerimeterPHARMA Solutions LLC, a consulting firm specializing in pharma/biotech commercialization strategies, sales force optimization, Japan business development and alliance management.

Prior to PerimeterPHARMA Solutions, Matt led the East Coast Oncology sales force for Myriad Genetics Labs after serving over 20 years at Eli Lily & Company where he held numerous leadership roles including sales leadership positions in the U.S., Head of Commercial Operations (marketing, new product planning, alliances) for Eli Lilly Japan KK, and Regional Business Unit Leader for Europe/Middle East and Africa.

Matt earned his BSc in Pharmacy from the University of Pittsburgh. He attended graduate business schools at the University of Miami and Louisiana State University as well as Executive Education programs at Duke University and Babson College.

About Aegle Therapeutics Corp.
Aegle Therapeutics is a clinical stage regenerative medicine company developing novel therapeutics based on its proprietary extracellular vesicle isolation technology. The company is isolating extracellular vesicles secreted by allogeneic bone marrow derived mesenchymal stem cells for the treatment of severe dermatological conditions. Aegle’s EV therapy is initially being developed to treat severe burns and epidermolysis bullosa, a rare connective tissue disorder, and prevent scarring.

For more information, visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bob Williamson